A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence (AI) method to make launching cancer clinical trials easier and faster.
A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.
Emmecell, a clinical-stage biotechnology company revolutionizing cell-based therapies for serious eye diseases, today announced exciting topline results from its U.S. multi-center Phase 1 extension study evaluating EO2002, a non-surgical cell therapy for corneal edema. The randomized, double-masked trial demonstrated significant improvements in vision and corneal health, alongside a strong safety profile.
The Speech Accessibility Project has two new partners — The Matthew Foundation and the Massachusetts Down Syndrome Congress — as it continues to recruit adults with Down syndrome who live in the United States and Canada. The project also allows residents of Puerto Rico to participate.
A team of Florida State University researchers led by Assistant Professor of Mathematics Bhargav Karamched has discovered that in a foraging ant’s search for food, it will leave pheromone trails connecting its colony to multiple food sources when they’re available, successfully creating the first model that explains the phenomenon of trail formation to multiple food sources.
An international team of neuro-oncology researchers and clinicians has released new recommendations for good clinical practice regarding the use of artificial intelligence methods to more accurately diagnose, monitor and treat brain cancer.
Researchers at UC San Diego and their colleagues have developed an optical biosensor that detects the virus that causes mpox. The technology could make diagnosis much faster and cost-effective as the disease continues to spread worldwide.
Researchers at the UChicago Medicine Comprehensive Cancer Center and Argonne National Laboratory are partnering to use AI approaches to discover new targets for cancer therapies
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by WashU Medicine researchers, the trial is the first to report results for this type of vaccine — known as a neoantigen DNA vaccine — for breast cancer patients.
Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a New England Journal of Medicine editorial published by Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center.
After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality of life, particularly in bowel and sexual health, compared to conventional CT-guided treatment.
The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to Rutgers Health researchers.
University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success using a gene therapy treatment in an animal model. The approach, which uses CRISPR-Cas9 genome editing technology, offers a unique and promising strategy that could one day treat rare but debilitating motor neuron diseases in humans.
UCLA investigators have shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.
Brief cognitive behavioral therapy for suicide prevention – when delivered remotely via video telehealth – reduces suicide attempts and suicidal ideation. The Ohio State University Wexner Medical Center and College of Medicine led the study that is published online in the journal JAMA Network Open.
Taking antibiotics during an influenza infection can be harmful and increases the risk of developing a bacterial pneumonia while sick with the flu, according to new research led by Cedars-Sinai.
The Cardiovascular Research Foundation® (CRF®) proudly announces the appointment of Dr. Jeffrey Popma as Chief Scientific and Strategic Officer. A world-renowned leader in cardiovascular research, Dr. Popma will drive forward pivotal programs and initiatives that will shape CRF’s future and fuel innovation at the CRF® Clinical Trials Center (CTC). His leadership will be instrumental in the development of the recently launched Real-World Data and Outcomes Center, advancing CRF’s commitment to impactful research. Additionally, as Program Director for New York Valves and TCT® (Transcatheter Cardiovascular Therapeutics®), CRF’s flagship scientific meeting, Dr. Popma will play a key role in guiding the organization’s transformative contributions to the field of cardiovascular medicine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
